Dr. Anthony Fauci – who has been considered one of the most trusted leaders tackling the COVID-19 pandemic in the United States – once again stressed that, as far as the evidence suggests, the novel coronavirus is naturally occurring and was not made in a laboratory.
Gilead Sciences Inc.’s experimental antiviral drug remdesivir helped improve outcomes for patients with COVID-19, and the company provided data suggesting the medicine worked better when given earlier in the course of infection.
Moderna Inc. submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for the company’s mRNA vaccine candidate against the novel coronavirus SARS-CoV-2 to evaluate mRNA-1273 in Phase 2 and late-stage studies if supported by safety data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Gilead Sciences Inc.’s shares surged 16 percent in after-hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
Cambridge, Massachusetts-based Moderna is one of the first companies to move a vaccine against COVID-19 into clinical trials.
The coronavirus outbreak could reach its peak in the United States this week, a top U.S. health official said as more signs of stabilization emerged, but political leaders said a reopening of the economy may hinge on more widespread testing.
Gilead Sciences is running at least five clinical trials for the company’s experimental antiviral drug remdesivir against COVID-19.
As American Christians began an Easter weekend under the threat of the coronavirus, political leaders cautioned the faithful not to gather in churches and the country’s top infectious disease expert urged people to stick with social distancing restrictions.
As the world shifts toward a concept of social distancing as part of an attempt to protect against the novel coronavirus, new research is showing the virus that causes COVID-19 is quite stable on hard surfaces, and even in the air.
Inside the United States, the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 begins today. The mRNA-1273 vaccine is being developed by Moderna Therapeutics with the National Institute of Allergy and Infectious Disease (NIAID).
